<p>Infection of TZM-bl indicator cells in the presence and absence of tenofovir was compared by luminescence analysis of cell lysates and the results expressed as percent inhibition. The graph shows the full titration of drug formulations on infection with SIV<sub>mac251/32H</sub>; the virus stock used in subsequent challenge experiments in vivo. Each point represents the mean of three independent experiments performed in triplicate +/− standard deviation. The results for a panel of HIV-1 strains in comparison to SIV<sub>mac251/32H</sub> are shown as IC<sub>50</sub> values in the inset.</p
<p>Virus inhibition assays were performed in PFA (A), MDM (B) and PBMC (C) using titrating amounts o...
<p>(<b>a</b>) SFT is more effective <i>in vitro</i> against HIV-1 subtype C pseudovirus than TFV. Th...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...
Tenofovir gel has entered into clinical trials for use as a topical microbicide to prevent HIV-1 inf...
models. To validate our findings with on-going clinical trial results, we evaluated topical tenofov...
<p>Peripheral blood mononuclear cells were activated and cultured with HIV-1 (BaL, laboratory-adapte...
Background: Tenofovir gel has entered into clinical trials for use as a topical microbicide to preve...
We compared the preclinical safety and efficacy of Tenofovir (TFV) 1% gel and MZC gel containing 50 ...
<p><b>A</b>, Cytotoxicity profile of SIL in TZM-bl cells. Cells were infected with LAI, a CXCR4-usin...
a<p>Data show the confidence interval (C.I.) based on the 2.5 and 97.5 percentiles of bootstrapped I...
The HIV reverse-transcriptase inhibitor, tenofovir, was recently formulated into a vaginal gel for u...
A vaginal gel containing 1 % tenofovir (TFV) was found to be safe and effective in reducing HIV infe...
Preclinical and early phase clinical microbicide studies have not consistently predicted the outcome...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...
<p>Virus inhibition assays were performed in PFA (A), MDM (B) and PBMC (C) using titrating amounts o...
<p>(<b>a</b>) SFT is more effective <i>in vitro</i> against HIV-1 subtype C pseudovirus than TFV. Th...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...
Tenofovir gel has entered into clinical trials for use as a topical microbicide to prevent HIV-1 inf...
models. To validate our findings with on-going clinical trial results, we evaluated topical tenofov...
<p>Peripheral blood mononuclear cells were activated and cultured with HIV-1 (BaL, laboratory-adapte...
Background: Tenofovir gel has entered into clinical trials for use as a topical microbicide to preve...
We compared the preclinical safety and efficacy of Tenofovir (TFV) 1% gel and MZC gel containing 50 ...
<p><b>A</b>, Cytotoxicity profile of SIL in TZM-bl cells. Cells were infected with LAI, a CXCR4-usin...
a<p>Data show the confidence interval (C.I.) based on the 2.5 and 97.5 percentiles of bootstrapped I...
The HIV reverse-transcriptase inhibitor, tenofovir, was recently formulated into a vaginal gel for u...
A vaginal gel containing 1 % tenofovir (TFV) was found to be safe and effective in reducing HIV infe...
Preclinical and early phase clinical microbicide studies have not consistently predicted the outcome...
Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...
<p>Virus inhibition assays were performed in PFA (A), MDM (B) and PBMC (C) using titrating amounts o...
<p>(<b>a</b>) SFT is more effective <i>in vitro</i> against HIV-1 subtype C pseudovirus than TFV. Th...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...